Pipeline / Eight programs

Built to phase gates.

Eight programs across rare disease, oncology, and immunology, all on the same editor platform and the same five phase gates. Nothing advances on narrative; a program advances on data.

The path

Five phases, one discipline.

  1. Discovery

    18 to 24 months

    Target triage and editor design. Tissue models, in-silico address maps, and a go or no-go inside eighteen months.

  2. Lead optimization

    12 to 18 months

    One editor per program. Top clone selected, process development started, and a GMP slot reserved.

  3. IND-enabling

    12 months

    GLP toxicology, whole-genome release data, and the CMC file assembled to specification.

  4. Phase 1/2

    24 to 36 months

    First in human. Safety, biomarker evidence of editing, and dose expansion in the target tissue.

  5. Registration

    36 months

    Pivotal design, market access, and the manufacturing network to supply a single-infusion therapy.

04 / Pipeline

The pipeline.

B1rde programs by edit, indication, modality, phase, and next readout
ProgramEditIndicationModalityPhaseNext readout
BRD-101

HbS mutation correction

HBB

Sickle cell disease

Rare disease

In-vivo editorPhase 1/2Interim data Q2 2027
BRD-301

G542X stop-codon correction

CFTR exon 12

Cystic fibrosis

Rare disease

In-vivo editorIND-enablingIND filing Q1 2027
BRD-103

F9 Padua knock-in

F9 exon 8

Hemophilia B

Rare disease

In-vivo editorLead optimizationPh1 start 2028
BRD-202

TRAC to CD19 CAR knock-in

TRAC locus

CD19+ B-cell malignancies

Oncology

Ex-vivo cell therapyLead optimizationPh1 start 2028
BRD-201

Y220C stabilizer potentiation

TP53

TP53-mutant solid tumors

Oncology

Editor-potentiatorDiscoveryCandidate 2027
BRD-203

SIRPa knockout armoring

SIRPa

Acute myeloid leukemia

Oncology

Ex-vivo cell therapyDiscoveryCandidate 2028
BRD-401

IL-2 locus rheostat edit

IL2 promoter

Refractory autoimmunity

Immunology

In-vivo editorDiscoveryCandidate 2028
BRD-402

HLA-E universal cloak edit

B2M locus

Allogeneic cell reservoirs

Immunology

Ex-vivo cell therapyDiscoveryCandidate 2029

All programs investigational. No approved indications. Phases per internal program review, September 2026.

Modes of action

  • In-vivo editor

    The editor is infused and gated to the target tissue. No cell collection, no conditioning.

  • Ex-vivo cell therapy

    Cells are edited outside the body with the same address-window chemistry, then returned.

  • Editor-potentiator

    A small molecule restores function at a mutant locus so the editor has something to write.